(-0.01%) 5 099.40 points
(0.18%) 38 309 points
(-0.03%) 15 923 points
(-1.34%) $82.73
(6.24%) $2.04
(0.00%) $2 347.10
(-0.25%) $27.47
(3.79%) $957.05
(-0.18%) $0.933
(-0.28%) $10.99
(-0.50%) $0.796
(1.75%) $93.48
0.00% $ 33.97
Live Chart Being Loaded With Signals
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide...
Stats | |
---|---|
Tagesvolumen | 5.63M |
Durchschnittsvolumen | 686 607 |
Marktkapitalisierung | 1.49B |
EPS | $0 ( 2023-05-04 ) |
Last Dividend | $0.125 ( 2019-02-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | 21.09 |
ATR14 | $0.299 (0.88%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-01-31 | Williams Felicia | Sell | 10 274 | Common Stock |
2023-01-31 | Williams Felicia | Sell | 12 000 | Stock Option (Right to Buy) |
2023-01-31 | Williams Felicia | Sell | 8 740 | Stock Option (Right to Buy) |
2023-01-31 | Williams Felicia | Sell | 17 205 | Stock Option (Right to Buy) |
2023-01-31 | Williams Felicia | Sell | 5 796 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-88.83 |
Last 100 transactions |
Buy: 118 571 | Sell: 1 534 678 |
Volumen Korrelation
Meridian Bioscience Inc Korrelation
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Meridian Bioscience Inc Korrelation - Währung/Rohstoff
Meridian Bioscience Inc Finanzdaten
Annual | 2022 |
Umsatz: | $333.02M |
Bruttogewinn: | $188.36M (56.56 %) |
EPS: | $0.960 |
FY | 2022 |
Umsatz: | $333.02M |
Bruttogewinn: | $188.36M (56.56 %) |
EPS: | $0.960 |
FY | 2021 |
Umsatz: | $317.90M |
Bruttogewinn: | $201.15M (63.27 %) |
EPS: | $1.650 |
FY | 2020 |
Umsatz: | $253.67M |
Bruttogewinn: | $156.25M (61.60 %) |
EPS: | $1.080 |
Financial Reports:
No articles found.
Meridian Bioscience Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00678 | 1990-11-29 |
Last Dividend | $0.125 | 2019-02-01 |
Next Dividend | $0 | N/A |
Payout Date | 2019-02-14 | |
Next Payout Date | N/A | |
# dividends | 114 | -- |
Total Paid Out | $9.88 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.53 | -- |
Div. Sustainability Score | 0.950 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.115 | -- |
Year | Amount | Yield |
---|---|---|
1990 | $0 | 0.00% |
1991 | $0 | 0.00% |
1992 | $0 | 0.00% |
1993 | $0 | 0.00% |
1994 | $0 | 0.00% |
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0.160 | 3.50% |
2004 | $0.178 | 3.83% |
2005 | $0.213 | 2.70% |
2006 | $0.307 | 2.09% |
2007 | $0.434 | 2.63% |
2008 | $0.560 | 1.88% |
2009 | $0.680 | 2.60% |
2010 | $0.760 | 3.51% |
2011 | $0.760 | 3.21% |
2012 | $0.950 | 4.98% |
2013 | $0.570 | 2.75% |
2014 | $0.800 | 3.06% |
2015 | $0.800 | 4.88% |
2016 | $0.800 | 4.10% |
2017 | $0.500 | 2.80% |
2018 | $0.500 | 3.47% |
2019 | $0.125 | 0.74% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.197 | 1.500 | -3.93 | -5.90 | [0 - 0.5] |
returnOnAssetsTTM | -0.0528 | 1.200 | -1.760 | -2.11 | [0 - 0.3] |
returnOnEquityTTM | -0.0681 | 1.500 | -1.867 | -2.80 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.56 | 0.800 | 2.18 | 1.741 | [1 - 3] |
quickRatioTTM | 1.472 | 0.800 | 6.05 | 4.84 | [0.8 - 2.5] |
cashRatioTTM | 0.943 | 1.500 | 5.87 | 8.81 | [0.2 - 2] |
debtRatioTTM | 0.0682 | -1.500 | 8.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -65.48 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.00825 | 2.00 | -0.00275 | -0.00550 | [0 - 30] |
freeCashFlowPerShareTTM | -0.148 | 2.00 | -0.0740 | -0.148 | [0 - 20] |
debtEquityRatioTTM | 0.0914 | -1.500 | 9.63 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.534 | 1.000 | 4.43 | 4.43 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.197 | 1.000 | -5.93 | -5.93 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.0116 | 1.000 | -1.176 | -1.176 | [0.2 - 2] |
assetTurnoverTTM | 0.268 | 0.800 | -1.544 | -1.235 | [0.5 - 2] |
Total Score | 0.950 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -61.83 | 1.000 | -6.35 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0681 | 2.50 | -1.200 | -2.80 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.148 | 2.00 | -0.0493 | -0.148 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.00825 | 2.00 | -0.00275 | -0.00550 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.518 | 1.500 | 3.22 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.00295 | 1.000 | -2.57 | 0 | [0.1 - 0.5] |
Total Score | -0.720 |
Meridian Bioscience Inc
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.